Ponazuril

Ponazuril

SCHEMBL29625926

Cc1cc(-n2c(=O)[nH]c(=O)n(C)c2=O)ccc1Oc1ccc(S(=O)(=O)C(F)(F)F)cc1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 12/20 0.55
NTRK2 Q16620 12/20 0.55
IGF1R P08069 4/20 0.55
FGFR1 P11362 4/20 0.55
NTRK3 Q16288 9/20 0.44
EPAS1 Q99814 4/20 0.39
PTPN1 P18031 1/20 0.39
BCAT2 O15382 2/20 0.37
BCAT1 P54687 2/20 0.37
ALDH3A1 P30838 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ponazuril SCHEMBL203030 1.00 NTRK1 (0.55) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL10527532 0.89 NTRK1 (0.55) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL10528041 0.89 EPAS1 (0.44) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL11475552 0.89 NTRK1 (0.44) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL20306614 0.89 NTRK1 (0.72) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL11474624 0.89 NTRK1 (0.56) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL10525700 0.88 NTRK1 (0.39) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL13780151 0.87 NTRK1 (0.60) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL10527978 0.87 NTRK1 (0.49) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL11490392 0.85 NTRK1 (0.41) NTRK1NTRK2IGF1RFGFR1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4021573-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS Alzecure Pharma AB (SE) 2022-07-06 EP disclosed
CN-114423743-A Triazine derivatives for the treatment of diseases associated with neurotrophic factors 阿泽克制药公司 2022-04-29 CN disclosed